Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06097468 · ClinicalTrials.gov registry record · Phase 1
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
A Phase 1 study of Oral Cavity Squamous Cell Carcinoma, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06097468: Recruiting Phase 1 study of Oral Cavity Squamous Cell Carcinoma, sponsored by University of California, San Francisco.
NCT06097468 is a Phase 1 study of Oral Cavity Squamous Cell Carcinoma that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 40 participants, below the 134-participant average among 8 other Oral Cavity Squamous Cell Carcinoma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06097468, a Phase 1 study of Oral Cavity Squamous Cell Carcinoma, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of California, San Francisco (UCSF).
Primary Outcome
Dose-limiting toxicities (DLTs) are defined in Section 5.2.3. DLT determination will assess adverse events (AEs) graded according to CTCAE v5.0, including findings on physical exam, vital signs, laboratory testing, and spontaneous reports of AEs reported to the investigator by participants. DLT data will be summarized as proportions of participants experiencing DLTs per cohort
Conditions Studied
Interventions
- DRUG NisinZ® P
- PROCEDURE Surgery (non-interventional, standard of care)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-02-02 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 1 |
What NCT06097468 shows while recruiting
NCT06097468 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 134-participant average among 8 other Oral Cavity Squamous Cell Carcinoma trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Oral Cavity Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which NisinZ® P is the first listed.
NCT06097468 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06097468 about?
NCT06097468 is a clinical study titled "Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)". This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of California, San Francisco (UCSF).
What is the current status of trial NCT06097468?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-02-02. Estimated completion is 2027-09-01.
What conditions does trial NCT06097468 study?
This clinical trial studies the following conditions: Oral Cavity Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06097468?
The interventions under investigation include: NisinZ® P (DRUG), Surgery (non-interventional, standard of care) (PROCEDURE).
Who is sponsoring clinical trial NCT06097468?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06097468 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oral Cavity Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06097468's enrollment target sits among peer trials
40 7th of 8 higher than 2 of 8 other Oral Cavity Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oral Cavity Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
RECRUITING · Phase 2
-
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
RECRUITING · Phase 2
-
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
RECRUITING · Phase 2
-
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RECRUITING · Phase 2
-
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
RECRUITING · Phase 2
-
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI